GRI Bio Inc. (NASDAQ: GRI) is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant NKT (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI’s lead program, GRI-0621, is an inhibitor of iNKT I cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis (IPF), a serious disease with significant unmet need. GRI is also developing a pipeline of novel type 2 natural killer T (NKT) cell agonists for the treatment of systemic lupus erythematosus and primary sclerosing cholangitis. Additionally, with a library of over 500 proprietary compounds, GRI has the ability to fuel a growing pipeline.